News Details

Eagle Pharmaceuticals Announces New Patent for RYANODEX


Eagle Pharmaceuticals, Inc. (Nasdaq:EGRX) (“Eagle” or “the Company”) today announced that the Company has been issued a new patent related to its RYANODEX® formulation (dantrolene sodium) by the United States Patent and Trademark Office (USPTO). Patent number 9,789,090 will expire in June 2022. The USPTO has now issued seven patents in the RYANODEX family of patents expiring from 2022 to 2025. The ‘090 patent is directed to a method of treating non-normothermia associated with recreational drug use utilizing Eagle’s RYANODEX formulation.

“We see significant value in RYANODEX and will continue to advance our work with multiple indications for which we believe the product could save lives. This additional patent strengthens our patent estate surrounding RYANODEX so that we may protect the value of our dantrolene sodium portfolio for many years to come,” stated Scott Tarriff, Chief Executive Officer of Eagle Pharmaceuticals.

RYANODEXis approved and marketed for the treatment of malignant hyperthermia. Eagle is currently exploring the use of RYANODEX for the treatment of multiple additional indications.

About Eagle Pharmaceuticals, Inc.

Eagle is a specialty pharmaceutical company focused on developing and commercializing injectable products that address the shortcomings, as identified by physicians, pharmacists and other stakeholders, of existing commercially successful injectable products. Eagle’s strategy is to utilize the FDA's 505(b)(2) regulatory pathway. Additional information is available on the company’s website at

Forward-Looking Statements

This press release contains forward-looking information within the meaning of the Private Securities Litigation Reform Act of 1995, as amended and other securities laws. Forward-looking statements are statements that are not historical facts. Words such as “will,” “continue,” “may,” “believe,” “intends,” “anticipate(s),” “plan,” “enables,” “potentially,” “entitles,” and similar expressions are intended to identify forward-looking statements. These statements include statements regarding future events including, but not limited to: Eagle’s ability to defend against third party attempts to design around or invalidate its patents covering Ryanodex; the timing and the outcome of any legal proceedings involving Ryanodex; successful compliance with FDA and other governmental regulations applicable to product approval, manufacturing facilities, products and/or businesses; the ability of Eagle to deliver sustained shareholder value over time ; and other factors that are discussed in Eagle’s Annual Report on Form 10-K for the year ended December 31, 2016, and its other filings with the U.S. Securities and Exchange Commission. All of such statements are subject to certain risks and uncertainties, many of which are difficult to predict and generally beyond Eagle’s control, that could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. Such risks include, but are not limited to whether Eagle’s management and/or board of directors will be effective in managing Eagle’s business and future growth, as well as the other risks described in Eagle’s filings with the U.S. Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date hereof, and we do not undertake any obligation to revise and disseminate forward-looking statements to reflect events or circumstances after the date hereof, or to reflect the occurrence of or non-occurrence of any events.

Investor Relations for Eagle Pharmaceuticals, Inc.:
Lisa M. Wilson, 212-452-2793